Komori
Changes in Officers4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Concerning Organizational Reorganization

Effective 1 December 2026, the Shimookui Plant will be abolished as an independent headquarters, and each department will be transferred to or integrated into the Production Headquarters, Reliability Assurance Headquarters and other units. In addition, the Production Management Oversight Division, Quality Assurance Oversight Division, Quality Control Oversight Division and Engineering Office will be newly established.

Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Reason for change

It was determined that further collaboration should be strengthened, with function-based reporting lines as the primary structure and the separation between headquarters eliminated.

Details of organizational changes

Abolish the Shimookui Plant as a headquarters; transfer the Active Pharmaceutical Ingredient Manufacturing Department and Production Management Department to the Production Headquarters, transfer the Quality Assurance Department and Quality Control Department to the Reliability Assurance Headquarters, and integrate the Environment and Safety Department into the Environment and Safety Office. Establish the Production Management Oversight Division, Quality Assurance Oversight Division, Quality Control Oversight Division and Engineering Office under the Production Headquarters.

Who is moving to which position
ItemDetails
Reason for changeIt was determined that further collaboration should be strengthened, with function-based reporting lines as the primary structure and the separation between headquarters eliminated.
Details of organizational changesAbolish the Shimookui Plant as a headquarters; transfer the Active Pharmaceutical Ingredient Manufacturing Department and Production Management Department to the Production Headquarters, transfer the Quality Assurance Department and Quality Control Department to the Reliability Assurance Headquarters, and integrate the Environment and Safety Department into the Environment and Safety Office. Establish the Production Management Oversight Division, Quality Assurance Oversight Division, Quality Control Oversight Division and Engineering Office under the Production Headquarters.
Items this document does not state (19)
Resolution dateScheduled Appointment DateDate of departureName of appointeeAppointee's new positionAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Following the absorption-type merger with 大和薬品工業, it was determined that further collaboration, including eliminating the separation between headquarters and primarily adopting function-based reporting lines, is necessary to achieve a true "ONE Daito."

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Organizational Reorganization | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori